Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 20th Preview)
-
Big Pharma M&A: Lilly expands pain pipeline with non-opioid mechanism
Eli Lilly agreed to acquire 4E Therapeutics, extending its push for non-opioid pain therapies at a time when the medical community remains focused on alternatives to opioid-based treatment. The Austin, Texas-based biotech’s lead program, 4ET1103, is designed around an MNK inhibitor approach aimed at blocking a pathway in peripheral sensory neurons rather than suppressing pain signaling in the brain. Lilly said 4E’s compounds target the MNK-eIF4E signaling pathway, which has been studied for its role in the transition from acute to chronic pain. 4E reported that 4ET1103 completed a Phase I safety study (NCT07586514), positioning the program for next steps within Lilly’s development and commercialization framework. The deal also builds on Lilly’s recent pain M&A activity, including the 2025 acquisition of SiteOne, and adds a new mechanism to its broader efforts to address chronic pain without central nervous system complications such as cognitive impairment and addiction risk.
-
Regulatory: FDA clears Diasorin rapid group A strep test for point-of-care PCR
The FDA granted 510(k) clearance and a CLIA waiver to Diasorin’s Liaison Nes rapid molecular group A strep test, giving clinicians a faster point-of-care option for acute pharyngitis. Diasorin said the assay delivers results in about 15 minutes with under one minute of hands-on time. Diasorin’s platform attributes include room-temperature reagent storage and a compact, cloud-connected device for real-time reporting in outpatient and decentralized settings. The new test is the second cleared assay on the Nes menu, after the company previously received clearance and CLIA waiver for a respiratory panel covering influenza A/B, RSV and COVID-19. Diasorin also tied the regulatory milestone to commercial targets outlined at an investor day, where executives projected Nes revenue exceeding $150 million by 2030, with a separate Liaison Plex gastrointestinal panel also cleared in May.
-
Immunology M&A: Biogen buys RayThera to broaden small-molecule immunology portfolio
Biogen moved to strengthen its immunology pipeline by acquiring RayThera in a deal valued at up to $1 billion. The acquisition adds multiple anti-inflammatory small-molecule assets to Biogen’s portfolio, with the lead candidate expected to enter Phase I clinical development in early Q3 2026. Biogen said it will provide an undisclosed upfront payment to RayThera shareholders, with most of the total consideration tied to future clinical and regulatory milestones. RayThera, founded by Qing Dong and Gene Hung, recently completed a $110 million Series A financing and built its immunology-focused discovery program around small-molecule approaches for immune-mediated conditions. The transaction adds to Biogen’s broader immunology M&A activity, which included an April acquisition of Apellis for $5.6 billion. Biogen positioned the RayThera buy as a way to create additional “shots on goal” across immune-driven disease areas and accelerate development of at least one candidate into human trials.
-
Clinical evidence synthesis: Systematic review quantifies second malignancies after T-cell engaging bispecifics
A systematic review and meta-analysis estimated the frequency of second primary malignant neoplasms (SPMs) after T-cell-engaging bispecific antibody therapy in adults with non-Hodgkin lymphoma and multiple myeloma. The study pools data across 20 studies (26 cohorts; 2,551 patients) and reports measurable long-term safety signals despite generally limited follow-up in the underlying trials. Researchers searched PubMed and Embase through October 1, 2025, following a PROSPERO-registered protocol and PRISMA-guided methods. Across eight included studies reporting total SPMs, the random-effects estimate was 3.5% (95% CI 1.8–6.9) at a median follow-up of 17.4 months. The analysis also found pooled estimates of 2.2% (95% CI 1.5–3.1) for SPMs leading to treatment discontinuation and 1.4% (95% CI 1.1–1.9) for SPMs leading to death. Authors reported no prespecified covariates—such as follow-up duration, disease category, prior therapy courses or age—were associated with total SPM rates, underscoring the need for longer observational data as bispecifics move earlier in treatment.
-
Neuroscience platform/data: DZNE launches NeuroGenomeHub with €6M to build neurodegeneration genome resource
Germany’s DZNE launched NeuroGenomeHub, a brain genomics initiative funded with about €6 million to build a global genome database for neurodegenerative diseases. DZNE said the project will sequence samples from roughly 25,000 individuals over the next two years, including data drawn from blood and other specimen types collected in ongoing DZNE studies. The initiative will leverage sequencing technologies such as long-read platforms and include DNA methylation analysis to enrich the database. DZNE said it will draw on resources including the Rhineland study in Bonn, which focuses on genetic underpinnings of healthy aging and dementia prevention. DZNE’s scientific director Joachim Schultze said the database is designed to identify genome-linked features that influence disease risk and progression, aiming to support future diagnostics, prevention strategies and therapies.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.